Eppion Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.95 Cr
- Satisfied Charges ₹ 14.80 Cr
- Revenue Growth -13.10%
- Profit Growth -35.46%
- Ebitda -29.69%
- Net Worth 31.75%
- Total Assets -45.49%
About Eppion Lifesciences
Eppion Lifesciences Private Limited (ELPL) is a Private Limited Indian Non-Government Company incorporated in India on 08 March 2016 (Eight years and 11 months 18 days old ). Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.95 Cr. The company has closed loans amounting to ₹14.80 Cr, as per Ministry of Corporate Affairs (MCA) records.
Raj Garg, Ankur Garg, Puneet Garg, and One other member serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U74999DL2016PTC292259
- Company No.
292259
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Mar 2016
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Eppion Lifesciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ankur Garg  | Director | 08-Mar-2016 | Current |
| Ameesh Garg | Director | 17-May-2021 | Current |
| Raj Garg | Director | 08-Mar-2016 | Current |
| Puneet Garg | Director | 08-Mar-2016 | Current |
Financial Performance of Eppion Lifesciences.
Eppion Lifesciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.1% decrease. The company also saw a substantial fall in profitability, with a 35.46% decrease in profit. The company's net worth Soared by an impressive increase of 31.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eppion Lifesciences?
In 2022, Eppion Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹99.50 M
₹148.00 M
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 9.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 16 Oct 2023 | Hdfc Bank Limited | ₹9.95 Cr | Open |
| 19 Feb 2021 | Others | ₹9.50 Cr | Satisfied |
| 25 Jan 2019 | Others | ₹5.30 Cr | Satisfied |
How Many Employees Work at Eppion Lifesciences?
Unlock and access historical data on people associated with Eppion Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eppion Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eppion Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.